No Data
cspc innovation pharmaceutical (300765.SZ): The application for the上市 of the ustekinumab injection by Giant Stone Biotechnology has been accepted.
On November 26, Gelonghui reported that cspc innovation pharmaceutical (300765.SZ) announced that its holding subsidiary cspc pharma Giant Stone Biopharmaceutical Co., Ltd. (hereinafter referred to as "Giant Stone Bio") recently received the "Acceptance Notification" issued by the National Medical Products Administration, and the market application for Ustekinumab injection has been accepted. Ustekinumab injection is a fully human IgG1κ monoclonal antibody that acts as an IL-12/IL-23p40 inhibitor; Ustekinumab specifically binds to the p40 protein subunit of IL-12 and IL-23 with high affinity, blocking IL-12 and IL-23.
CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) Market Cap Dropped CN¥3.3b Last Week; Public Companies Bore the Brunt
cspc innovation pharmaceutical (300765.SZ): Giant Stone Biological's therapeutic vaccine SYS6026 has been approved to conduct clinical trials.
Gelonghui November 12th | CSPC Innovation Pharmaceutical (300765.SZ) announced that the holding subsidiary, CSPC Pharma Group JuShi Biopharmaceutical Co., Ltd. (hereinafter referred to as 'JuShi Bio'), recently received the Drug Clinical Trial Approval Notice for the therapeutic vaccine SYS6026 targeting HPV-induced related precancerous lesions issued by the National Medical Products Administration, and will conduct clinical trials in the near future. SYS6026 is the first therapeutic vaccine independently developed based on the company's mRNA platform, delivered by messenger RNA (mRNA) molecules combined with lipid nanoparticles (LNP).
Express News | CSPC Innovation Pharmaceutical Says Key Shareholder Plans to Raise Stake in Company for 100-120 Mln Yuan Within Six Months
cspc innovation pharmaceutical (300765.SZ): The controlling shareholder plans to increase its shareholding by 0.1 billion yuan to -0.12 billion yuan in the company's shares.
Gelonghui November 7th | CSPC Innovation Pharmaceutical (300765.SZ) announced that the company recently received a notification from the controlling shareholder cspc pharma's Enbipu Pharmaceutical Co., Ltd. (referred to as Enbipu Pharmaceutical), Enbipu Pharmaceutical plans to increase its shareholding in the company within six months from the disclosure date of this announcement (including this date), with the amount not less than RMB 100 million and not more than RMB 120 million.
Is CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) Worth CN¥29.2 Based On Its Intrinsic Value?
No Data
No Data